A philosophy professor argues that prenatal genetic testing allows potentially painful afflictions to be discovered prior to birth and does not unjustly discriminate against disabled people.
A physicians urges practitioners to use cost-effective alternatives to dispensing samples to patients who cannot afford to pay for their prescriptions.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
While there are benefits to genetic screening during pregnancy, parents must not let their desire for a genetically perfect child allow them to terminate a pregnancy because of non-medical factors.
Physicians need to take an active role in improving the genetic literacy of the general population and also push for public health policies that make new genetic tools available to everyone.